Lipocine (LPCN) Total Current Liabilities (2011 - 2025)
Lipocine's (LPCN) quarterly Total Current Liabilities came in at $2.5 million in Q4 2025, up 67.11% YoY from $1.5 million in Q4 2024, and up 30.92% on a QoQ basis from $1.9 million in Q3 2025.
Lipocine (LPCN) Total Current Liabilities (2011 - 2025) Analysis & Trends
Lipocine (LPCN) has 15 years of Total Current Liabilities data on file, last reported at $2.5 million in Q4 2025.
- Quarterly Total Current Liabilities rose 67.11% year-over-year to $2.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.5 million (up 67.11% YoY) and the FY2025 annual result came in at $2.5 million, up 67.11% from the prior year.
- Total Current Liabilities improved to $2.5 million in Q4 2025, from $1.9 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $8.8 million in Q2 2021 to a low of $1.3 million in Q1 2025.
- A 5-year average of $2.8 million and a median of $1.9 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Current Liabilities jumped 108.15% — and 2022, when it tumbled 80.55%.
- Tracing LPCN's Total Current Liabilities over 5 years: stood at $5.6 million in 2021, then slumped by 70.12% to $1.7 million in 2022, then jumped by 56.82% to $2.6 million in 2023, then plunged by 42.51% to $1.5 million in 2024, then surged by 67.11% to $2.5 million in 2025.
- The last three Total Current Liabilities figures came in at $2.5 million (Q4 2025), $1.9 million (Q3 2025), and $1.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | 2.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.53 Mn |
| Sep 30, 2025 | 1.93 Mn |
| Jun 30, 2025 | 1.45 Mn |
| Mar 31, 2025 | 1.30 Mn |
| Dec 31, 2024 | 1.51 Mn |
| Sep 30, 2024 | 1.58 Mn |
| Jun 30, 2024 | 1.82 Mn |
| Mar 31, 2024 | 1.49 Mn |
| Dec 31, 2023 | 2.63 Mn |
| Sep 30, 2023 | 2.24 Mn |
| Jun 30, 2023 | 1.83 Mn |
| Mar 31, 2023 | 1.93 Mn |
| Dec 31, 2022 | 1.68 Mn |
| Sep 30, 2022 | 1.51 Mn |
| Jun 30, 2022 | 1.71 Mn |
| Mar 31, 2022 | 3.52 Mn |
| Dec 31, 2021 | 5.62 Mn |
| Sep 30, 2021 | 6.43 Mn |
| Jun 30, 2021 | 8.81 Mn |
| Mar 31, 2021 | 5.40 Mn |